



State of Utah

SPENCER J. COX
Governor

DEIDRE M. HENDERSON
Lieutenant Governor

Insurance Department

JONATHAN T. PIKE
Insurance Commissioner

2024 Utah Pharmacy Premium Impact Report

Introduction

Utah Code § 31A-48-103(2) requires health insurers to submit pharmacy drug information to the Utah Insurance Department (Department) on or before August 1st each year. The Department must publish this information on its website by December 1st each year. The Department must also ensure that the identity of the health insurers is protected.

A health insurer shall report to the Department, in aggregate, the following information for health benefit plans offered by the insurer:

- 1) For the 25 drugs for which spending by the health insurer was the greatest, after adjusting for rebates: the name of the drug, the dosage form of the drug, and the strength of the drug.
- 2) The percentage increase over the previous year in net spending for all drugs, after adjusting for rebates.
- 3) The percentage of the increase in premiums over the previous year attributable to all drugs and specialty drugs.

Data was collected from health insurers issuing comprehensive health insurance health benefit plans in Utah during 2023. These companies represent over 99 percent of the comprehensive health insurance market. These health insurers provide coverage for an estimated 22.6 percent of Utah residents and represent fully insured comprehensive health benefit plans only. The data does not include any information from employer sponsored health benefit plans or government sponsored health benefit plans. Utah health insurers not actively issuing comprehensive health insurance health benefit plans were excluded

The data was aggregated to produce market level estimates of the Top 25 drugs with the largest spending by health insurers, after adjusting for rebates, in the comprehensive health insurance market. Premium impact was measured by estimating the percentage of comprehensive health insurance premiums attributable to pharmacy drug costs for the Top 25 drugs, generic drugs, brand name drugs, specialty drugs, and all drugs.

Generic drugs. A generic drug, as classified by the United States Food and Drug Administration (FDA), is therapeutically equivalent to a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use. A generic drug is not under patent protection and may be produced by more than one pharmacy drug manufacturer.

Brand name drugs. A brand name drug, as classified by the United States Food and Drug Administration (FDA), is a drug marketed under a proprietary, trademark-protected name. The drug has patent protection and is usually produced by only one pharmacy drug manufacturer until the patent protection has expired.

Specialty drugs. A generic or brand name drug classified as a specialty drug on the health insurer's drug formulary list are prescription drug products that require special handling, has high costs, or are only available through specialty pharmacies.

Total (All drugs). Total (all drugs) includes all generic, brand name, and specialty drugs as reported by the health insurer.

Top 25 drugs. The Top 25 drugs described in this report are a subset of all drugs and may include generic, brand name, or specialty drugs. Each health insurer was asked to report the top 25 drugs with the largest insurer spending, after adjusting for rebates, by the National Drug Code (NDC). This information was combined to generate the Top 25 drugs with the largest insurer spending for the comprehensive health insurance market.

Cost PMPM. Pharmacy drug spending was measured by cost PMPM. Cost PMPM is the total pharmacy drug spending by the health insurer, after adjusting for rebates, divided by cumulative member months. A member month is the total number of members covered by the health insurer's health benefit plan for a single month. Cumulative member months is the sum total of member months for the calendar year. This method standardizes pharmacy drug costs per member per month for a health insurer.

Premium. Premium income was measured using the same method as cost PMPM. The total direct earned premium reported by the health insurer was divided by the total cumulative member months. Direct earned premium is the premium income received by the health insurer from all sources (after risk adjustment) that was allocated to the health insurer's loss experience, expenses, and profit during the year.

Executive Summary

- The top 25 drugs accounted for 34.8% of total drug spending for all drugs in 2023
- The top 25 drugs accounted for 9.77% of premiums in 2023
- The top 5 drugs with the highest insurer spending in Utah were Humira, Trikafta, Stelara, Enbrel, and Trulicity
- Spending for all drugs increased by 24.0% between 2022 and 2023 due to increases in brand name and specialty drugs
- Premiums increased by 6.6% between 2022 and 2023
- The percentage of premium attributable to all drugs increased 3.7% between 2022 and 2023

Top 25 Drugs in the Comprehensive Health Insurance Market

Table 1 shows the 25 drugs with the largest health insurer spending in the comprehensive health insurance market in Utah. Drugs were ranked by the total dollar amount of drug spending by health insurers for the market as a whole. Table 1 lists these drugs by their proprietary name and includes the 11-digit NDC for the dosage, as well as the package form of the drug. The non-proprietary name of the drug and its manufacturer are provided in Table 2 (see Table 2).

The Top 25 drugs accounted for 34.8 percent of total drug spending across all types of drugs and were attributable to 9.77 percent of comprehensive health insurance premiums. The top 5 drugs that accounted for the largest percentage of comprehensive health insurance premiums were Humira, Trikafta, Stelara, Enbrel and Trulicity. These drugs accounted for 51.8 percent of the total drug spending for the Top 25 drugs and made up 4.8 percent of comprehensive health insurance premiums. In most cases, the Top 25 drugs were classified as specialty drugs. However, fifteen drugs were classified as brand name drugs by at least one health insurer. None of the Top 25 drugs were generic drugs.

Table 1. Top 25 Drugs in the 2023 Comprehensive Health Insurance Market by Health Insurer Pharmacy Drug Spending

Rank	Proprietary Name	Drug Type	11-digit NDC(s)	Dosage Form	Strength	Cost PMPM	Percent of Premium
1	HUMIRA	S	00074012402	Injection	80 mg/0.8 mL	\$8.23	1.92%
		S	00074012403		80 mg/0.8 mL		
		S	00074024302		40 mg/0.4 mL		
		S	00074055402		40 mg/0.4 mL		
		S	00074433902		40 mg/.8 mL		
2	TRIKAFTA ^a	S	51167010602	Tablet	50 mg-25 mg-37.5 mg-75 mg	\$3.75	0.87%
		B/S	51167033101		100 mg-50 mg-75 mg-150 mg		
3	STELARA	S	57894006003	Injection	45 mg/0.5 mL	\$3.16	0.74%
		S	57894006103		90 mg/mL		
4	ENBREL	S	58406002104	Injection	50 mg/mL	\$2.91	0.68%
		S	58406003204		50 mg/mL		
		S	58406004404		50 mg/mL		
5	TRULICITY	B	00002143380	Injection	0.75 mg/0.5 mL	\$2.36	0.55%
		B	00002143401		1.5 mg/0.5 mL		
		B	00002143480		1.5 mg/0.5 mL		
		B	00002223680		3 mg/0.5 mL		
		B	00002318280		4.5 mg/0.5 mL		
6	DUPIXENT	B/S	00024591401	Injection	300 mg/2 mL	\$2.07	0.48%
		B/S	00024591502		300 mg/2 mL		
7	OCREVUS	S	50242015001	Injection	300 mg/10 mL	\$1.76	0.41%
8	TYSABRI	S	64406000801	Injection	300 mg/15 mL	\$1.65	0.38%
9	SKYRIZI	S	00074105001	Injection	150 mg/mL	\$1.58	0.37%
		S	00074210001		150 mg/mL		
10	RINVOQ	S	00074230630	Tablet	15 mg	\$1.57	0.37%
		S	00074231030		30 mg		

11	ENTYVIO	S	64764030020	Injection	300 mg	\$1.42	0.33%
		S	00006302601		100 mg/ 4mL		
12	KEYTRUDA	S	00006302602	Injection	100 mg/ 4mL	\$1.37	0.32%
		S	00006302604		100 mg/ 4mL		
13	COSENTYX	S	00078063941	Injection	300 mg/mL	\$1.24	0.29%
		S	00078063968		150 mg/mL		
14	JARDIANCE	B	00597015230	Tablet	10 mg	\$0.79	0.19%
		B	00597015330		25 mg		
15	LANTUS	B	00088221905	Injection	100 mL	\$0.79	0.18%
16	BIKTARVY ^b	B/S	61958250101	Tablet	50 mg-200 mg-25 mg	\$0.78	0.18%
17	ELIQUIS	B	00003089421	Tablet	5 mg	\$0.77	0.18%
18	FARXIGA	B	00310621030	Tablet	10 mg	\$0.73	0.17%
19	SPRAVATO	S	50458002803	Solution	84 mg	\$0.61	0.14%
20	XOLAIR	S	50242021501	Injection	150 mg/mL	\$0.59	0.14%
		S	50242092101		60 mg/.4 mL		
21	HEMLIBRA	S	50242092201	Injection	105 mg/0.7 mL	\$0.42	0.10%
		S	50242092301		150 mg/mL		
22	OPDIVO	S	00003373413	Injection	240 mg/24 mL	\$0.33	0.08%
23	DARZALEX	S	57894050301	Injection	1800 mg/15 mL	\$0.19	0.04%
24	DESCOVY ^c	B/S	61958200201	Tablet	200 mg/25 mg	\$0.17	0.04%
		S	42747020301		20 mg/mL		
25	CRYSVITA	S	42747030401	Injection	30 mg/mL	\$0.15	0.04%
		S	69794020301		20 mg/mL		
		S	69794030401		30 mg/mL		

Source: Utah Insurance Department, 2024 Utah Pharmacy Premium Impact Survey

Note: B = Brand name, G = Generic, S = Specialty. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2023.

^a Trikafta: 4-wallets (each containing 14 tablets of elexacaftor, tezacaftor, and ivacaftor and 7 tablets of ivacaftor)

^b Biktarvy: contains bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate

^c Descovy: contains emtricitabine and tenofovir alafenamide

Table 2. Top 25 Drugs in the 2023 Comprehensive Health Insurance Market by Drug Manufacturer

Rank	Proprietary Name	Nonproprietary Name	Labeler Code	Company Name
1	Humira	adalimumab	0074	AbbVie Inc.
2	Trikafta	elexacaftor, tezacaftor, and ivacaftor	51167	Vertex Pharmaceuticals Incorporated
3	Stelara	ustekinumab	57894	Janssen Biotech, Inc.
4	Enbrel	etanercept	58406	Immunex Corporation
5	Trulicity	dulaglutide	0002	Eli Lilly and Company
6	Dupixent	dupilumab	0024	Sanofi-Aventis U.S. LLC
7	Ocrevus	ocrelizumab	50242	Genentech, Inc.
8	Tysabri	natalizumab	64406	Biogen Inc.
9	Skyrizi	risankizumab-rzaa	0074	AbbVie Inc.
10	Rinvoq	upadacitinib	0074	AbbVie Inc.
11	Entyvio	vedolizumab	64764	Takeda Pharmaceuticals America, Inc.
12	Keytruda	pembrolizumab	0006	Merck Sharp & Dohme LLC
13	Cosentyx	secukinumab	0078	Novartis Pharmaceuticals Corporation
14	Jardiance	empagliflozin	0597	Boehringer Ingelheim Pharmaceuticals, Inc.
15	Lantus	insulin glargine	0088	Sanofi-Aventis U.S. LLC
16	Biktarvy	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	61958	Gilead Sciences, Inc.
17	Eliquis	apixaban	0003	E.R. Squibb & Sons, L.L.C.
18	Farxiga	dapagliflozin	0310	AstraZeneca Pharmaceuticals LP
19	Spravato	esketamine hydrochloride	50458	Janssen Pharmaceuticals Inc.
20	Xolair PFS	omalizumab	50242	Genentech, Inc.
21	Hemlibra	emicizumab	50242	Genentech, Inc.
22	Opdivo	nivolumab	0003	E.R. Squibb & Sons, L.L.C.
23	Darzalex	daratumumab	57894	Janssen Biotech, Inc.
24	Descovy	emtricitabine and tenofovir alafenamide	61958	Gilead Sciences, Inc.
25	Crysvita	burosumab	69794	Ultragenyx Pharmaceutical Inc.

Source: Utah Insurance Department, 2024 Utah Pharmacy Premium Impact Survey

Pharmacy Drug Spending

In addition to reporting the Top 25 drugs by total drug spending, health insurers also reported the total drug spending for generic, brand, specialty, and all drugs. Drug spending was measured by the amount paid by the health insurer for each drug type category.

Generic drugs accounted for 9.9 percent of spending across all drugs. Brand name drugs accounted for 23.8 percent, and specialty drugs accounted for 66.3 percent of total drug spending for all drugs. Total drug spending for all drugs increased by 24 percent from 2022 to 2023. Generic drug spending decreased 14.6 percent. Brand name drug spending increased by 28.6 percent. Specialty drug spending increased by 31.1 percent (see Table 3).

Table 3. 2023 Health Insurer Pharmacy Drug Spending as a Percent of Pharmacy Drug Costs

Drug Type	Cost PMPM	Percent of Drug Spending	Percent Change in Cost PMPM
Generic	\$11.33	9.9%	-14.6%
Brand	\$27.36	23.8%	28.6%
Specialty	\$76.20	66.3%	31.1%
Total (All Drugs)	\$114.89	100.0%	24.0%

Source: Utah Insurance Department, 2024 Utah Pharmacy Premium Impact Survey

Note: Percent change is the annual percent change from the previous year. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2023.

Premium Attributable to Pharmacy Drug Spending

In 2023, the percentage of comprehensive health insurance premiums attributable to total drug spending for all drugs was 26.8 percent and for specialty drugs was 17.8 percent (see Table 4).

Based on the available data, the Department estimates that the percentage of comprehensive health insurance premiums attributable to total drug spending for all drugs increased about 3.7 percentage points from 2022 to 2023. The increase in total drug spending appears to be due to an increase in spending for brand name and specialty drugs (see Table 4).

Table 4. 2023 Percent of Premium Attributable to Health Insurer Pharmacy Drug Spending

Drug Type	Cost PMPM	Percent Change in Cost PMPM	Percent of Premium	Net Change in Percent of Premium
Generic	\$11.33	-14.6%	2.6%	-0.7%
Brand	\$27.36	28.6%	6.4%	1.1%
Specialty	\$76.20	31.1%	17.8%	3.3%
Total (All Drugs)	\$114.89	24.0%	26.8%	3.7%

Premium	\$428.73	6.6%	100.0%	-
---------	----------	------	--------	---

Source: Utah Insurance Department, 2024 Utah Pharmacy Premium Impact Survey

Note: Percent change is the annual percent change from the previous year. Net change is the difference in the percent of premium from the previous year. Estimates may not add up exactly due to rounding. All data is current as of Dec. 31, 2023.

The 2024 Pharmacy Premium Impact Report was published by the Utah Insurance Department on December 1, 2024. For questions, please contact the Health & Life Division at (801) 957- 9280 or health.uid@utah.gov.